血管内皮増殖因子（VEGF）阻害剤の世界市場レポート 2025年

血管内皮増殖因子（VEGF）阻害剤市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.3％で594億8,000万米ドルに成長します。予測期間の成長は、がん有病率の増加、加齢黄斑変性（AMD）有病率の上昇、ヘルスケア支出の増加、新興国の高い潜在力、バイオシミラー医薬品の高い普及率、高齢者人口の増加などに起因すると考えられます。予測期間における主な動向としては、進行がんと闘い患者の生活を改善するために併用療法を患者に提供すること、イノベーションを促進しカテゴリーリーダーを確立するために戦略的提携に注力すること、効果的で革新的な医薬品を開発するために研究開発活動に幅広く投資すること、治療をより安価にすることでより広い市場に対応するためにバイオシミラーの生産に注力すること、患者の福祉を改善するために湿潤型加齢黄斑変性（AMD）の投与量を減らすことに注力することなどが挙げられます。

がんと黄斑変性症の有病率の上昇は、VEGF阻害剤市場の成長を促進すると予想されています。例えば、2023年1月、米国を拠点とする健康団体である米国がん協会の報告書では、米国における2023年の白血病の新規患者数は全種類で約59,610人、関連する死亡者数は約23,710人と予測されています。さらに、急性骨髄性白血病（AML）は、推定20,380人の新規患者と約11,310人の死亡者を占めると予想されています。このように、がんと黄斑変性症の有病率の増加は、予測期間中の血管内皮増殖因子（VEGF）阻害剤市場の成長をサポートすると予測されています。

高齢者人口の拡大は、VEGF阻害剤市場の成長をさらに促進するとみられます。65歳以上の高齢者と定義される老年人口は、加齢に伴う変化によりヘルスケアニーズが高まっています。この人口層は、ヘルスケアの進歩、生活環境の改善、慢性疾患管理の向上により寿命が延びるにつれて増加しています。VEGF阻害剤は特に高齢者に有益であり、この年齢層に多い特定のがんや眼疾患を含む加齢に伴う疾患をターゲットとしています。例えば、2022年10月、スイスに本部を置く国際的な公衆衛生機関である世界保健機関（WHO）の報告書によると、2030年までに世界の6人に1人が60歳以上になり、2050年までにこの数は21億人に達すると予測されています。その結果、高齢化人口の増加がVEGF阻害剤市場の需要を押し上げると予想されます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界血管内皮増殖因子（VEGF）阻害剤PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の血管内皮増殖因子（VEGF）阻害剤市場：成長率分析
• 世界の血管内皮増殖因子（VEGF）阻害剤市場の実績：規模と成長, 2019-2024
• 世界の血管内皮増殖因子（VEGF）阻害剤市場の予測：規模と成長, 2024-2029, 2034F
• 世界血管内皮増殖因子（VEGF）阻害剤総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の血管内皮増殖因子（VEGF）阻害剤市場薬の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• アバスチン
• テセントリク
• コメトリック
• アイレア
• その他の薬物の種類
• 世界の血管内皮増殖因子（VEGF）阻害剤市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 静脈内
• 世界の血管内皮増殖因子（VEGF）阻害剤市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 腫瘍学
• 眼科
• その他の用途
• 世界の血管内皮増殖因子（VEGF）阻害剤市場アバスチンのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 腫瘍学アプリケーション
• 眼科アプリケーション
• 世界の血管内皮増殖因子（VEGF）阻害剤市場、テセントリクのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 非小細胞肺がん
• 小細胞肺がん
• 膀胱がん
• トリプルネガティブがん
• 世界の血管内皮増殖因子（VEGF）阻害剤市場ルセンティスの薬剤タイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 滲出型加齢黄斑変性症（AMD）
• 糖尿病網膜症
• 網膜静脈閉塞症
• 世界の血管内皮増殖因子（VEGF）阻害剤市場タグリッソのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 第一選択治療
• 第二選択治療
• 世界の血管内皮増殖因子（VEGF）阻害剤市場、Cometriqのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 甲状腺髄様がん
• 腎細胞がん
• 世界の血管内皮増殖因子（VEGF）阻害剤市場、Eyleaのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 滲出型加齢黄斑変性症（AMD）
• 糖尿病黄斑浮腫（DME）
• 網膜静脈閉塞症（RVO）
• 世界の血管内皮増殖因子（VEGF）阻害剤市場、その他の薬剤タイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 免疫腫瘍薬
• 抗血管新生剤
• その他のモノクローナル抗体

第7章 地域別・国別分析

• 世界の血管内皮増殖因子（VEGF）阻害剤市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の血管内皮増殖因子（VEGF）阻害剤市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 血管内皮増殖因子（VEGF）阻害剤市場：競合情勢
• 血管内皮増殖因子（VEGF）阻害剤市場：企業プロファイル
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Regeneron Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca Plc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Pfizer Inc.
• Eli Lilly and Company
• Exelixis Inc.
• Amgen Inc.
• Sanofi S.A.
• Cipla Limited
• Biocon
• Dr. Reddy's Laboratories
• Chi-Med
• Innovent Biologics
• Daiichi Sankyo
• Chugai Pharmaceutical Co. Ltd
• Boehringer Ingelheim International GmbH
• GlaxoSmithKline plc
• Ipsen

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 血管内皮増殖因子（VEGF）阻害剤市場2029：新たな機会を提供する国
• 血管内皮増殖因子（VEGF）阻害剤市場2029：新たな機会を提供するセグメント
• 血管内皮増殖因子（VEGF）阻害剤市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

A Vascular Endothelial Growth Factor (VEGF) inhibitor is a substance that hinders programmed cell death by acting as an anti-apoptotic factor for hematopoietic cells. VEGF, a growth factor, promotes vascular permeability, potentially facilitating the spread of tumors through the bloodstream and enhancing their access to oxygen and nutrients.

The primary categories of VEGF inhibitors include Avastin, Tecentriq, Cometriq, Eylea, and others. Avastin is a medication designed to assist individuals with wet age-related macular degeneration (AMD). Additionally, it is utilized to treat diabetic eye issues and other retinal conditions. Administered into the eye, Avastin helps delay the loss of eyesight associated with certain disorders. Various routes of administration, including oral and intravenous, are employed in the fields of oncology, ophthalmology, and other medical domains.

The vascular endothelial growth factor (VEGF) inhibitor market research report is one of a series of new reports from The Business Research Company that provides vascular endothelial growth factor (VEGF) inhibitor market statistics, including vascular endothelial growth factor (VEGF) inhibitor industry global market size, regional shares, competitors with a vascular endothelial growth factor (VEGF) inhibitor market share, detailed vascular endothelial growth factor (VEGF) inhibitor market segments, market trends and opportunities, and any further data you may need to thrive in the vascular endothelial growth factor (VEGF) inhibitor industry. This vascular endothelial growth factor (VEGF) inhibitor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The vascular endothelial growth factor (VEGF) inhibitor market size has grown strongly in recent years. It will grow from $43.44 billion in 2024 to $46.64 billion in 2025 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to increase in cancer prevalence, strong economic growth in emerging markets, increase in pharmaceutical R&D expenditure, increased healthcare expenditure, government initiatives and rapid growth in elderly population.

The vascular endothelial growth factor (VEGF) inhibitor market size is expected to see strong growth in the next few years. It will grow to $59.48 billion in 2029 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to increasing prevalence of cancer, rising prevalence of age-related macular degeneration (AMD), rise in healthcare expenditure, high potential of emerging economies, high penetration of the biosimilar drugs and increasing geriatric population. Major trends in the forecast period include offering combination therapies to patients in order to combat advanced cancers and improve patient life, focusing on strategic collaborations to boost innovations and establish category leadership, investing extensively in R&D activities for the development of effective and innovative drugs, focusing on the production of biosimilars in order to cater to a wider market by making treatment more affordable and focusing on reducing dosages for wet age-related macular degeneration (AMD) in order to improve patient welfare.

The rising prevalence of cancer and macular degeneration is expected to drive the growth of the VEGF inhibitor market. For example, in January 2023, a report by the American Cancer Society, a U.S.-based health organization, projected approximately 59,610 new cases of leukemia across all types and around 23,710 related fatalities in 2023 in the United States. Additionally, acute myeloid leukemia (AML) is expected to account for an estimated 20,380 new cases and about 11,310 deaths. Thus, the increasing prevalence of both cancer and macular degeneration is anticipated to support growth in the vascular endothelial growth factor (VEGF) inhibitor market over the forecast period.

The expanding geriatric population is likely to further drive the VEGF inhibitor market's growth. Defined as individuals aged 65 and above, the geriatric population has increased healthcare needs due to age-related changes. This demographic is growing as advancements in healthcare, improved living conditions, and better chronic disease management increase life expectancy. VEGF inhibitors are particularly beneficial for older adults, targeting age-associated diseases, including certain cancers and ocular conditions, which are more common in this age group. For instance, in October 2022, a report by the World Health Organization (WHO), a Switzerland-based international public health agency, projected that one in six people globally will be aged 60 or older by 2030, with this number reaching 2.1 billion by 2050. Consequently, the increasing aging population is expected to boost demand in the VEGF inhibitor market.

Key players in the VEGF inhibitor industry are increasingly engaging in collaborations and partnerships to broaden their product portfolios by developing new treatments. Product portfolio expansion is a strategic approach enabling companies to grow their businesses and increase market share by meeting consumer demand. This development process encompasses the stages of conceptualization, design, creation, and marketing of newly introduced or rebranded products or services. For example, in April 2024, Santen Pharmaceutical Co. Ltd., a Japan-based pharmaceutical firm, partnered with Bayer Yakuhin, a Japanese pharmaceutical and life sciences company, to launch the Ophthalmic VEGF Inhibitor Eylea 8mg Solution for Intravitreal Injection at a concentration of 114.3 mg/mL. This treatment targets conditions like age-related macular degeneration (nAMD) and diabetic macular edema (DME), both of which can cause vision loss. With a higher concentration than prior versions, Eylea 8mg offers an extended dosing interval of up to 16 weeks, minimizing the need for frequent injections while ensuring continued efficacy and safety. This partnership aims to expand the availability of this advanced ophthalmic solution, reducing the treatment burden on patients and setting a new standard of care.

Major companies in the VEGF inhibitors market are dedicated to introducing innovative products through collaborations to maximize their revenues. Collaborative innovation involves developing new ideas, products, or services through partnerships with external entities such as customers, suppliers, and other stakeholders. For instance, in June 2022, Biogen Inc., a US-based biotechnology company, and Samsung Bioepis Co. Ltd., a South Korea-based biopharmaceutical company, jointly launched BYOOVIZ (ranibizumab-nuna), a biosimilar referencing LUCENTIS (ranibizumab). BYOOVIZ, the first ophthalmology biosimilar in the United States, offers expanded alternatives and cost reduction for existing anti-VEGF treatments. It can be used to treat conditions such as Myopic Choroidal Neovascularization (mCNV), Macular Edema Following Retinal Vein Occlusion (RVO), and Neovascular (Wet) Age-Related Macular Degeneration (AMD), as it is a vascular endothelial growth factor (VEGF) inhibitor.

In January 2023, Takeda Pharmaceutical Company Limited, a Japan-based pharmaceutical company, acquired the worldwide license for Fruquintinib, a highly selective oral VEGFR1/2/3 tyrosine kinase inhibitor, from HUTCHMED Limited for an undisclosed amount. Under the agreement, Takeda gains exclusive global rights to develop and market fruquintinib for all indications and regions outside mainland China, Hong Kong, and Macau. HUTCHMED Limited, a China-based pharmaceutical company, specializes in the development of vascular endothelial growth factor receptor (VEGFR) 1/2/3.

Major companies operating in the vascular endothelial growth factor (VEGF) inhibitor market include F. Hoffmann-La Roche AG, Bayer AG, Regeneron Pharmaceuticals Inc., AstraZeneca Plc., Novartis AG, Pfizer Inc., Eli Lilly and Company, Exelixis Inc., Amgen Inc., Sanofi S.A., Cipla Limited, Biocon, Dr. Reddy's Laboratories, Chi-Med, Innovent Biologics, Daiichi Sankyo, Chugai Pharmaceutical Co. Ltd, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Ipsen, Oxurion, Pharmstandard Group, Zentiva, Coherus BioSciences Inc., AVEO pharmaceuticals, Eisai Co. Ltd.

North America was the largest region in the vascular endothelial growth factor (VEGF) inhibitor market in 2024. Middle East is expected to be the fastest-growing region in the vascular endothelial growth factor (VEGF) inhibitor market share during the forecast period. The regions covered in the vascular endothelial growth factor (VEGF) inhibitor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the vascular endothelial growth factor (VEGF) inhibitor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The vascular endothelial growth factor (VEGF) inhibitor market consists of sales of nexavar, sunitinib, nilotinib, pazopanib, and dasatinib. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Vascular Endothelial Growth Factor (VEGF) Inhibitor Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on vascular endothelial growth factor (vegf) inhibitor market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for vascular endothelial growth factor (vegf) inhibitor ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The vascular endothelial growth factor (vegf) inhibitor market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drugs Type: Avastin, Tecentriq, Lucentis, Tagrisso, Cometriq, Eylea, Other Drug Types
• 2) By Route Of Administration: Oral, Intravenous, Intravitreal
• 3) By Application: Oncology, Ophthalmology, Other Applications
• Subsegments:
• 1) By Avastin: Oncology Applications; Ophthalmology Applications
• 2) By Tecentriq: Non-Small Cell Lung Cancer; Small Cell Lung Cancer; Bladder Cancer; Triple-Negative Breast Cancer
• 3) By Lucentis: Wet Age-Related Macular Degeneration (AMD); Diabetic Retinopathy; Retinal Vein Occlusion
• 4) By Tagrisso: First-Line Treatment; Second-Line Treatment
• 5) By Cometriq: Medullary Thyroid Cancer; Renal Cell Carcinoma
• 6) By Eylea: Wet Age-Related Macular Degeneration (AMD); Diabetic Macular Edema (DME); Retinal Vein Occlusion (RVO)
• 7) By Other Drug Types: Immuno-Oncology Drugs; Anti-Angiogenic Agents; Other Monoclonal Antibodies
• Companies Mentioned: F. Hoffmann-La Roche AG; Bayer AG; Regeneron Pharmaceuticals Inc.; AstraZeneca Plc.; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Characteristics

3. Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Trends And Strategies

4. Vascular Endothelial Growth Factor (VEGF) Inhibitor Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Growth Analysis And Strategic Analysis Framework

• 5.1. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Growth Rate Analysis
• 5.4. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Total Addressable Market (TAM)

6. Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Segmentation

• 6.1. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Avastin
• Tecentriq
• Cometriq
• Eylea
• Other Drug Types
• 6.2. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Intravenous
• 6.3. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oncology
• Ophthalmology
• Other Applications
• 6.4. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Sub-Segmentation Of Avastin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oncology Applications
• Ophthalmology Applications
• 6.5. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Sub-Segmentation Of Tecentriq, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Non-Small Cell Lung Cancer
• Small Cell Lung Cancer
• Bladder Cancer
• Triple-Negative Cancer
• 6.6. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Sub-Segmentation Of Lucentis, By Drugs Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Wet Age-Related Macular Degeneration (AMD)
• Diabetic Retinopathy
• Retinal Vein Occlusion
• 6.7. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Sub-Segmentation Of Tagrisso, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• First-Line Treatment
• Second-Line Treatment
• 6.8. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Sub-Segmentation Of Cometriq, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Medullary Thyroid Cancer
• Renal Cell Carcinoma
• 6.9. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Sub-Segmentation Of Eylea, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Wet Age-Related Macular Degeneration (AMD)
• Diabetic Macular Edema (DME)
• Retinal Vein Occlusion (RVO)
• 6.10. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immuno-Oncology Drugs
• Anti-Angiogenic Agents
• Other Monoclonal Antibodies

7. Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Regional And Country Analysis

• 7.1. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

• 8.1. Asia-Pacific Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

• 9.1. China Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview
• 9.2. China Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

• 10.1. India Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

• 11.1. Japan Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview
• 11.2. Japan Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

• 12.1. Australia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

• 13.1. Indonesia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

• 14.1. South Korea Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview
• 14.2. South Korea Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

• 15.1. Western Europe Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview
• 15.2. Western Europe Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

• 16.1. UK Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

• 17.1. Germany Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

• 18.1. France Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

• 19.1. Italy Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

• 20.1. Spain Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

• 21.1. Eastern Europe Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview
• 21.2. Eastern Europe Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

• 22.1. Russia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

• 23.1. North America Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview
• 23.2. North America Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

• 24.1. USA Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview
• 24.2. USA Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

• 25.1. Canada Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview
• 25.2. Canada Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

• 26.1. South America Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview
• 26.2. South America Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

• 27.1. Brazil Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

• 28.1. Middle East Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview
• 28.2. Middle East Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

• 29.1. Africa Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview
• 29.2. Africa Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Competitive Landscape And Company Profiles

• 30.1. Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Competitive Landscape
• 30.2. Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Regeneron Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AstraZeneca Plc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Other Major And Innovative Companies

• 31.1. Pfizer Inc.
• 31.2. Eli Lilly and Company
• 31.3. Exelixis Inc.
• 31.4. Amgen Inc.
• 31.5. Sanofi S.A.
• 31.6. Cipla Limited
• 31.7. Biocon
• 31.8. Dr. Reddy's Laboratories
• 31.9. Chi-Med
• 31.10. Innovent Biologics
• 31.11. Daiichi Sankyo
• 31.12. Chugai Pharmaceutical Co. Ltd
• 31.13. Boehringer Ingelheim International GmbH
• 31.14. GlaxoSmithKline plc
• 31.15. Ipsen

32. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

34. Recent Developments In The Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

35. Vascular Endothelial Growth Factor (VEGF) Inhibitor Market High Potential Countries, Segments and Strategies

• 35.1 Vascular Endothelial Growth Factor (VEGF) Inhibitor Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Vascular Endothelial Growth Factor (VEGF) Inhibitor Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Vascular Endothelial Growth Factor (VEGF) Inhibitor Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer